Clinical Trials · NCT03990194
Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate Cancer
- Phase
- N/A
- Recruitment status
- Withdrawn
- Sponsor
- RECORDATI GROUP
- Enrollment
- 0
- Start date
- Mar 2020
- Locations
- See registry
- Primary endpoint
- The percentage of prostate cancer patients at 3 months who attained a testosteronemia threshold of ≤ 0.5 ng/mL following a 3-month treatment with leuprorelin 5 mg implant